All In Biotech

Drug Trial Radar · NCT03120949

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,106

Actual

Start

Jul 4, 2017

Primary completion

Sep 1, 2021

Study completion Sep 1, 2021

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
IQVIA Pvt. Ltd; OCT Clinical Trials
First posted
Apr 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Olokizumab 64 mg SC q4wDrug

    160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.

  • Olokizumab 64 mg SC q2wDrug

    160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.

  • Concomitant treatmentDrug

    Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.) Folic acid ≥ 5 mg per week or equivalent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)Time frame: up to Week 126
  2. Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)Time frame: up to Week 126
  3. Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)Time frame: up to Week 126
  4. Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study TreatmentTime frame: up to Week 126
  5. Incidence Rate of Treatment Emergent AEs Per Patient-years of ExposureTime frame: up to Week 126
  6. Incidence Rate of Treatment Emergent SAEs Per Patient-years of ExposureTime frame: up to Week 126
  7. Incidence Rate of Treatment Emergent AESIs (Safety Population)Time frame: up to Week 126

Locations

239 sites in 18 countries. Site status is shown where the registry gives one.

  • AZ Arthritis & Rheum' Research

    Mesa, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Sun City, Arizona

  • CHI St. Vincent Hot Springs

    Hot Springs, Arkansas

  • Medvin Clinical Research

    Covina, California

  • C.V Mehta MD Med Corp..

    Hemet, California

  • Advanced Medical Research, LLC

    La Palma, California

  • Valerius Medical Group

    Los Alamitos, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Rheumatology Center of San Diego

    San Diego, California

  • East Bay Rheumatology Medical Group, Inc.

    San Leandro, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • Center for Rheumatology Research, Comprehensive Rheumatology Center

    West Hills, California

  • Medvin Clinical Research

    Whittier, California

  • Denver Arthritis Clinic

    Denver, Colorado

  • New England Research Associates LLC

    Bridgeport, Connecticut

  • Javed Rheumatology Associates

    Newark, Delaware

  • RASF - Clinical Research Center

    Boca Raton, Florida

  • Reliable Clinical Research, LLC

    Hialeah, Florida

  • Pharmax Research Clinic

    Miami, Florida

  • Medical Research Center of Miami

    Miami, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • Omega Research Consultants

    Orlando, Florida

  • Arthritis Research of Florida, INC

    Palm Harbor, Florida

  • Family Clinical Trials, LLC.

    Pembroke Pines, Florida

  • AdventHealth Medical Group, PA

    Tampa, Florida

  • Lovelace Scientific Resources, Inc.

    Venice, Florida

  • Arthritis Center of North Georgia

    Gainesville, Georgia

  • Marietta Rheumatology Associates, PC

    Marietta, Georgia

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • University of Kansas Hospital

    Kansas City, Kansas

  • Graves Gilbert Clinic

    Bowling Green, Kentucky

  • The Arthritis & Diabetes Clinic, Inc.

    Monroe, Louisiana

  • Klein and Associates, M.D., P.A.

    Hagerstown, Maryland

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • AA MRC LLC Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • North MS Medical Clinics, Inc.

    Tupelo, Mississippi

  • Glacier View Research Institute-Rheumatology

    Kalispell, Montana

  • Physician Research Collaboration

    Lincoln, Nebraska

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.